

# SUPPLEMENTARY TABLES

## Table of Contents

<b>SUPPLEMENTARY TABLES</b> .....	<b>35</b>
Supplementary Table 1. Search strategy used to identify relevant systematic reviews and meta-analyses on the association between time to cancer diagnosis and treatment and outcomes of interest. ....	<b>36</b>
Supplementary Table 2. Characteristics of systematic reviews on the association between time to cancer diagnosis and treatment and clinical outcomes. ....	<b>37</b>
Supplementary Table 3. Characteristics of included meta-analyses on the association between time to cancer diagnosis and treatment and clinical outcomes. ....	<b>38</b>

**Supplementary Table 1.** Search strategy used to identify relevant systematic reviews and meta-analyses on the association between time to cancer diagnosis and treatment and outcomes of interest

Search term	Search number	Keywords/MeSH terms
Cancer	1	'neoplasm'/exp OR (Neoplasms) OR (Cancer) OR (Cancers) OR (Neoplasia) OR (Neoplasm) OR (Tumors) OR (Tumor) OR (Malignancy) OR (Malignancies) OR (Malignant Neoplasms) OR (Malignant Neoplasm) OR (Neoplasm Benign)
Diagnosis & Treatment	2	(Diagnosis) OR (diagnose) OR (treat) OR (treatment) OR (therapy) OR (care) OR (screen) OR (surgery) OR (radiation therapy) OR (systemic therapy) OR (chemotherapy) OR (adjuvant chemotherapy) OR (adjuvant radiotherapy) OR (neoadjuvant chemotherapy) OR (neoadjuvant radiotherapy)
Exposure	3	(delay) OR (wait time) or (postpone) OR (interval) OR (deferred) OR (deferral) OR (time to surgery) OR (time to treatment) OR (waiting period) OR (patient delay) OR (provider delay) OR (doctor delay) OR (time to treatment initiation) OR (system delay) OR (doctor delay) OR (professional delay) OR (time interval) OR (postponement) OR (time to diagnosis)
Outcome	4	(outcomes) OR (recurrence) OR (survival) OR (mortality) OR (tumour progression) OR (postoperative complications) OR (oncologic outcomes) OR (disease free survival) OR (overall survival) OR (pathological complete response) OR (recurrence free survival) OR (local recurrence) OR (metastasis) OR (progression free survival)
Study type	5	(systematic review) OR (meta-analysis) OR (metanalyses) OR (systematic reviews)
Aggregation of search terms	6	1 AND 2 AND 3 AND 4 AND 5
Limits	7	Limit 6 to yr="2010-2019"

The search was performed on 15 February 2021, limiting to publications from before the COVID-19 pandemic (1 January 2010 - 31 December 2019), with no restriction on publication language.

**Supplementary Table 2.** Characteristics of included systematic reviews on the association between time to cancer diagnosis and treatment and clinical outcomes

First author (year)	Databases searched	Number of hits	Number of included studies	Total Number of participants	Countries in which studies were conducted
Brasme (2012) (28)	EMBASE, Science Citation Index, Google Scholar	6,412	98	22,619	Not reported
van den Bergh (2013) (24)	PubMed and EMBASE	4,950	17	34,517	Not reported
Doubeni (2018) (30)	MEDLINE	4,979	8	77,035	Canada, France, USA
Foster (2013) (26)	MEDLINE, EMBASE	2,111	16	2,628	Not reported
Lethaby (2013) (29)	Medline, EMBASE, EMBASE Classic, Centre for Reviews and Dissemination databases, Cochrane Library, Medline In-Process, Other Non-Indexed Citations	1,665	32	11,016	France, Denmark, Israel, UK, Japan, Switzerland, Germany, Canada, USA, China, Brazil, Belgium, Italy, Hong Kong, Singapore, Turkey, South Africa, Nigeria, Sweden
Neal (2015) (20)	MEDLINE, MEDLINE in-process, EMBASE, Cumulative Index to Nursing and Allied Health Literature, PsychINFO, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, Cochrane Database of Systematic Reviews, Health Technology Assessment Database, NHS Economic Evaluation database.	193,077	117	401,706	UK, Italy, Spain, Netherlands, Denmark, Finland, France, Norway, Switzerland, Sweden, Germany, Poland, Austria, Belgium, Romania, Greece, Denmark, India, Japan, China, Hong Kong, Malaysia, South Korea, USA, Canada, Brazil, Turkey, Israel, Australia, New Zealand, Saudi Arabia, Libya, South Africa
Graboyes (2018) (23)	PubMed, EMBASE, Cumulative Index to Nursing and Allied Health Literature, Cochrane Library	Not reported	5	Not reported	Netherlands, USA, Canada, South Korea
Hansen (2018) (22)	PubMed, EMBASE, Cumulative Index to Nursing and Allied Health Literature, Cochrane Library	3,259	5	13,514	Denmark, USA, Canada, South Korea
Mattosinho (2019) (27)	PubMed/MEDLINE, Literatura Latino-Americana e do Caribe em Ciências da Saúde, Scientific Electronic Library Online	434	9	1,560	Brazil, Honduras, Chile, Argentina, Peru, México
Warren (2019) (25)	PubMed, EMBASE, MEDLINE	575	10	30,298	Not reported

**Supplementary Table 3.** Characteristics of, and subgroup and/or sensitivity analysis reported by included meta-analyses on the association between time to cancer diagnosis and treatment and clinical outcomes

First author (year)	Databases searched	Number of hits	Number of included studies	Total number of participants	Subgroup and/or Sensitivity analyses			Countries in which studies were conducted						
					Covariate	Response variable of interest	Pooled risk estimate [95% CI] (model type, heterogeneity statistics I <sup>2</sup> or Ri)							
Gomez (2009) (37)	MEDLINE, EMBASE, and ISI proceedings	Not reported	9	1,895	Cancer type	TNM (Oral)	<b>OR:1.47 [1.09–1.99]</b> (fixed-effects) <b>OR:1.55 [0.96–2.51]</b> (random-effects, Ri = 0.55)	USA, Israel, Canada, Finland, Greece, Thailand, Japan, Brazil, UK						
						TNM (Oral delay >1 month)	<b>OR:1.69 [1.26–2.77]</b> (fixed-effects) <b>OR:1.41 [0.73–2.75]</b> (random-effects, Ri = 0.80)							
					Study Quality	TNM (High-quality)	<b>OR: 1.40 [1.11–1.76] (fixed-effects)</b> OR: 1.31 [0.83–2.07] (random-effects, Ri= 0.74)							
						TNM (low-quality)	OR: 1.01 [0.62–1.65] OR: 1.14 [0.48–2.74] (random-effects, Ri= 0.39)							
					Follow-up period	TNM (≥ 10 year)	<b>OR: 1.40 [1.11–1.76]</b> OR: 1.31 [0.83–2.07] (random-effects, Ri=0.74)							
						TNM (< 10 year)	OR: 1.01 [0.62–1.65] OR: 1.14 [0.48–2.74] (random-effects, Ri= 0.67)							
					Stratification by site	TNM (Yes)	<b>OR: 1.51 [1.19–1.90]</b> OR: 1.47 [0.93–2.32] (random-effects, Ri= 0.73)							
						TNM (No)	OR: 0.85 [0.55–1.31] OR: 0.93 [0.49–1.79] (random-effects, Ri= 0.54)							
					Confounding adjustment (tobacco smoking, alcohol consumption)	TNM (Yes)	OR: 1.06 [0.83–1.35] OR: 1.02 [0.72–1.43] (random-effects, Ri= 0.46)							
						TNM (No)	OR: 2.26 [1.54–3.32] OR: 2.13 [0.97–4.67] (random-effects, Ri= 0.74)							
					Des Guetz (2010) (43)	PubMed	42		11	17,645	Excluding the 2 largest studies	Mortality	<b>RR:1.14 [1.04–1.25]</b>	Not reported
											Cut-off delays between surgery and AC	Mortality	<b>RR:1.18 [1.13–1.23]</b>	
												Mortality (Colon)	<b>HR: 1.25 [1.17-1.34]</b>	

					Studies on Colon cancer	Mortality (Stage III colon)	<b>HR: 1.25 [1.18-1.33]</b>	
Biagi (2011) (44)	MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials	198	10	15,410	Excluding the 2 largest studies	Mortality	<b>HR: 1.15 [1.10-1.22]</b>	Not reported
					Excluding the 3 largest studies	Mortality	<b>HR: 1.13 [1.10-1.17]</b>	
					Excluding the 3 largest studies	Cancer-specific survival	<b>HR: 1.15 [1.10-1.19]</b>	
Seoane (2012) (19)	MEDLINE, EMBASE, ISI Proceedings	1,016	10	1,286	Cancer type	Mortality (oral cancer)	RR: 1.00 [0.92-1.10] (fixed-effects) RR: 1.27 [0.81-1.98] (random-effects, Ri = 0.94)	Finland, Spain, USA, Denmark
						Mortality (pharynx cancer)	<b>RR: 1.68 [1.22-2.31]</b> (fixed-effects) <b>RR: 1.69 [1.05-2.72]</b> (random-effects, Ri = 0.55)	
						Mortality (larynx cancer)	<b>RR: 1.05 [1.02-1.08]</b> (fixed-effects) RR: 1.64 [0.91-2.96] (random-effects, Ri = 1.00)	
					Percentage of cases in stage III and IV	Mortality ( $\geq 60\%$ )	<b>RR: 1.74 [1.30-2.33]</b> (fixed-effects) <b>RR: 1.76 [1.21-2.54]</b> (random-effects, Ri = 0.37)	
						Mortality ( $<60\%$ )	<b>RR: 1.04 [1.01-1.07]</b> (fixed-effects) RR: 1.19 [0.99-1.44] (random-effects, Ri = 0.96)	
					Study design	Mortality (retrospective)	<b>RR: 1.09 [1.00-1.19]</b> (fixed-effects) <b>RR: 1.57 [1.11-2.24]</b> (random-effects, Ri = 0.92)	
						Mortality (partially prospective)	<b>RR: 1.04 [1.01-1.07]</b> (fixed-effects) RR: 1.34 [0.69-2.61] (random-effects, Ri = 1.00)	
					Primary care centres	Mortality	<b>RR: 1.50 [1.25-1.79]</b> (fixed-effects) <b>RR: 1.77 [1.14-2.73]</b> (random-effects, Ri = 0.81)	
						Questionnaires	Mortality	
					Study participants	Mortality (population-based)	RR: 1.02 [0.92-1.11] (fixed-effects) RR: 1.16 [0.82-1.65] (random-effects, Ri = 0.89)	
							Mortality (hospital-based)	
						Mortality	<b>RR: 1.09 [1.00-1.19]</b> (fixed-effects)	

					Source of mortality data unknown		<b>RR: 1.68 [1.13–2.49]</b> (random-effects, Ri = 0.94)	
					Source of data unknown	Mortality	<b>RR: 1.04 [1.01-1.07]</b> (fixed-effects) RR: 1.17 [0.85–1.60] (random-effects, Ri = 0.99)	
					Adjusted for Sex	Mortality (yes)	<b>RR: 1.04 [1.01-1.07]</b> (fixed-effects) RR: 1.16 [0.99–1.36] (random-effects, Ri = 0.94)	
						Mortality (no)	<b>RR: 2.77 [1.81-4.24]</b> (fixed-effects) <b>RR: 2.77 [1.81–4.24]</b> (random-effects, Ri = 0.00)	
					Study quality	Mortality (study quality score $\geq 4$ )	<b>RR: 1.54 [1.28-1.86]</b> (fixed-effects) <b>RR: 1.77 [1.14–2.75]</b> (random-effects, Ri = 0.81)	
						Mortality (study quality score $< 4$ )	<b>RR: 1.04 [1.012-1.07]</b> (fixed-effects) RR: 1.04 [0.93–1.17] (random-effects, Ri = 0.89)	
Yu (2013) (40)	PubMed, EMBASE, Cochrane Library, Web of Science	1,157	7	34,097	Stepwise exclusion	Mortality (1 study)	<b>HR: 1.17 [1.12-1.22]</b>	Italy, France, Denmark, USA
						Mortality (2 studies)	<b>HR: 1.23 [1.12-1.34]</b>	
Seoane (2015) (18)	MEDLINE, EMBASE, Web of Science	653	10	1,023	Study quality	TNM, T1, T2, T4, or T11, high quality	<b>RR: 2.44 [1.36–4.36]</b> (fixed-effects) <b>RR: 2.44 [1.36–4.36]</b> (random-effects, Ri = 0.00)	Canada, Thailand, Finland, Netherlands, UK, Argentina, Spain
						TNM, T1, T2, T4, or T11, low quality	<b>RR: 1.53 [1.26–1.86]</b> (fixed-effects) <b>RR: 1.53 [1.12–2.08]</b> (random-effects, Ri = 0.55)	
Wang (2015) (33)	PubMed, Cochrane Library, EMBASE	3,053	15	4,431	Time interval	pCR rate (5 weeks)	RR: 0.67 [0.40-1.12]	Not reported
						pCR rate (6 weeks)	RR: 1.03 [0.76-1.42]	
						pCR rate (7 weeks)	<b>RR: 1.45 [1.18-1.78]</b>	
						pCR rate (8 weeks)	<b>RR: 1.49 [1.15-1.92]</b>	
						pCR rate (10 weeks)	RR: 0.83 [0.65-1.06]	
						pCR rate (12 weeks)	RR: 0.81 [0.60-1.08]	
Gupta (2016) (31)	MEDLINE, EMBASE, Cochrane Register of Controlled Trials	Not reported	11 included in primary analysis (34 included in review)	79,616 (of the 34 studies)	Treatment sequencing vs non-sequencing studies	LR (sequencing)	RR: 1.08 [0.98-1.19] (fixed-effects)	Not reported
						LR (non-sequencing)	<b>RR: 1.08 [1.01-1.15]</b> (fixed-effects)	
						Mortality (sequencing)	RR: 1.0 [0.94-1.06] (fixed-effects)	
						Mortality (non-sequencing)	RR: 0.98 [0.87-1.10] (fixed-effects)	
						LR	<b>RR: 1.07 [1.03-1.10]</b>	

					Inclusion of all studies regardless of quality	Mortality	<b>RR: 1.06 [1.04-1.07]</b>	
Petrelli (2016) (34)	PubMed, EMBASE, Web of Science, Cochrane Library	5,065	13	3,584	--			Not reported
Raphael (2016) (41)	MEDLINE, EMBASE	1,326	14	56,269	Study type	Mortality (RCT)	RR: 1.06 [0.97-1.16] (random effects)	Denmark, Italy, France, Canada, US, England, New Zealand
						Mortality (institution-based cohort study)	<b>RR: 1.20 [1.00-1.44]</b> (random effects)	
						Mortality (population-based cohort study)	<b>RR: 1.43 [1.43-1.69]</b> (random effects)	
					Validity	Worsened DFS (high validity only)	<b>RR: 1.04 [1.00-1.08]</b>	
						Worsened DFS (not high validity)	RR: 1.06 [0.97-1.15]	
						Worsened DFS (high validity)	RR: 1.06 [0.99 -1.12] (random effects)	
						Worsened DFS (not high validity)	RR: 1.06 [0.97 -1.15] (random effects)	
Du (2017) (36)	PubMed, EMBASE, and Cochrane Library	1,914	13	19,652	Stepwise exclusion	pCR	<b>RR: 1.25 [1.16-1.35]</b>	Not reported
							<b>RR: 1.25 [1.16-1.35]</b>	
							<b>RR: 1.31 [1.07-1.60]</b>	
							<b>RR: 1.25 [1.16-1.35]</b>	
							<b>RR: 1.26 [1.16-1.36]</b>	
							<b>RR: 1.27 [1.17-1.37]</b>	
							<b>RR: 1.25 [1.16-1.35]</b>	
							<b>RR: 1.25 [1.16-1.36]</b>	
							<b>RR: 1.25 [1.16-1.35]</b>	
							<b>RR: 1.25 [1.15-1.35]</b>	
					<b>RR: 1.24 [1.15-1.35]</b>			
<b>RR: 1.26 [1.17-1.36]</b>								
Waiting interval	pCR (7-weeks)	<b>RR: 1.51 [1.20-1.89]</b>						
Lin (2017) (38)	MEDLINE, EMBASE, Clinical Trials, Cochrane Central Register of Controlled Trials.	2,622	5	1,016	Stepwise exclusion	2-year OS, 5-year OS, pCR, postoperative mortality, anastomotic leakage	--	Italy, USA, Taiwan, France

Liu (2017) (46)	PubMed, Web of Science	5,277	14	59,569	Study design	Mortality (prospective) (Categorical lag-time variable)	<b>HR: 1.22 [1.02-1.46] (random-effects, I<sup>2</sup> = 48.7%)</b>	(Continent only provided) Asia, North America, Europe
						Mortality (retrospective) (Categorical lag-time variable)	<b>HR: 1.08 [1.01-1.15] (random-effects, I<sup>2</sup> = 0%)</b>	
					Geographic location	Mortality (Asia) (Categorical lag-time variable)	HR: 1.06 [0.80-1.38] (random-effects, I <sup>2</sup> = NA)	
						Mortality (North America) (Categorical lag-time variable)	HR: 1.11 [0.94-1.32] (random-effects, I <sup>2</sup> = 87.7%)	
						Mortality (Europe) (Categorical lag-time variable)	<b>HR: 1.25 [1.05-1.29] (random-effects, I<sup>2</sup> = 21.6%)</b>	
					Number of cases	Mortality (<600) (Categorical lag-time variable)	HR: 1.16 [0.83-1.62] (random-effects, I <sup>2</sup> = 60.6%)	
						Mortality (≥600) (Categorical lag-time variable)	<b>HR: 1.15 [1.02-1.29] (random-effects, I<sup>2</sup> = 77.6%)</b>	
					Residual disease	Mortality (Yes) (Categorical lag-time variable)	HR: 0.69 [0.30-1.60] (random-effects, I <sup>2</sup> = NA)	
						Mortality (No) (Categorical lag-time variable)	HR: 1.35 [0.51-3.57] (random-effects, I <sup>2</sup> = NA)	
					Chemotherapy	Mortality (Platinum-based) (Categorical lag-time variable)	HR: 1.26 [0.98-1.63] (random-effects, I <sup>2</sup> = 7.8%)	
						Mortality (Platinum-based plus Taxane) (Categorical lag-time variable)	HR: 1.17 [1.04-1.32] (random-effects, I <sup>2</sup> = 65.9%)	
					FIGO stage	Mortality (All) (Categorical lag-time variable)	HR: 1.09 [0.93-1.28] (random-effects, I <sup>2</sup> = 0%)	
						Mortality (III–IV) (Categorical lag-time variable)	<b>HR: 1.23 [1.07-1.42] (random-effects, I<sup>2</sup> = 81.5%)</b>	



					Mortality (I-II) (Categorical lag-time variable)	HR: 0.78 [0.51-1.19] (random-effects, I <sup>2</sup> = NA)
				Adjustment for FIGO staging as potential confounder	Mortality (Yes) (Categorical lag-time variable)	<b>HR: 1.16 [1.04-1.30] (random-effects, I<sup>2</sup> = 70.9%)</b>
					Mortality (No) (Categorical lag-time variable)	HR: 0.92 [0.48-1.77] (random-effects, I <sup>2</sup> = NA)
				Adjustment for histology as a potential confounder	Mortality (Yes) (Categorical lag-time variable)	HR: 1.07 [0.91-1.26] (random-effects, I <sup>2</sup> = 36.7%)
					Mortality (No) (Categorical lag-time variable)	<b>HR: 1.26 [1.19-1.34] (random-effects, I<sup>2</sup> = 0%)</b>
				Adjustment for residual disease as a potential confounder	Mortality (Yes) (Categorical lag-time variable)	<b>HR: 1.22 [1.10-1.36] (random-effects, I<sup>2</sup> = 23.5%)</b>
					Mortality (No) (Categorical lag-time variable)	HR: 1.09 [0.89-1.34] (random-effects, I <sup>2</sup> = 62.6%)
				Study design	Mortality (prospective) (Continuous lag-time variable)	<b>HR: 1.06 [1.00-1.12] (random-effects, I<sup>2</sup> = 0%)</b>
					Mortality (retrospective) (Continuous lag-time variable)	HR: 1.04 [0.97-1.13] (random-effects, I <sup>2</sup> = 69.1%)
				Geographic location	Mortality (Asia) (Continuous lag-time variable)	<b>HR: 1.15 [1.04-1.27] (random-effects, I<sup>2</sup> = NA)</b>
					Mortality (North America) (Continuous lag-time variable)	<b>HR: 1.01 [1.00-1.02] (random-effects, I<sup>2</sup> = 0%)</b>
					Mortality (Europe) (Continuous lag-time variable)	<b>HR: 1.06 [1.00-1.12] (random-effects, I<sup>2</sup> = 0%)</b>
				Number of cases	Mortality (<600)	<b>HR: 1.07 [1.00-1.15] (random-effects, I<sup>2</sup> = 44.2%)</b>

					(Continuous lag-time variable)	
					Mortality ( $\geq 600$ ) (Continuous lag-time variable)	<b>HR: 1.01 [1.0-1.02] (random-effects, <math>I^2 = 55.8\%</math>)</b>
				Residual disease	Mortality (Yes) (Continuous lag-time variable)	<b>HR: 1.09 [1.01-1.78] (random-effects, <math>I^2 = 0\%</math>)</b>
					Mortality (No) (Continuous lag-time variable)	HR: 0.98 [0.94-1.03] (random-effects, $I^2 = 0\%$ )
				Chemotherapy	Mortality (Platinum-based) (Continuous lag-time variable)	HR: 1.00 [0.90-1.11] (random-effects, $I^2 = NA$ )
					Mortality (Platinum-based plus Taxane) (Continuous lag-time variable)	HR: 1.02 [0.99-1.05] (random-effects, $I^2 = 26.2\%$ )
					Mortality (NA) (Continuous lag-time variable)	<b>HR: 1.15 [1.04-1.27] (random-effects, <math>I^2 = NA</math>)</b>
				FIGO stage	Mortality (All) (Continuous lag-time variable)	HR: 1.03 [0.93-1.14] (random-effects, $I^2 = NA$ )
					Mortality (III–IV) (Continuous lag-time variable)	HR: 1.05 [0.99-1.11] (random-effects, $I^2 = 66.4\%$ )
				Adjustment for FIGO staging as potential confounder	Mortality (Yes) (Continuous lag-time variable)	HR: 1.05 [0.99-1.11] (random-effects, $I^2 = 66.4\%$ )
					Mortality (No) (Continuous lag-time variable)	HR: 1.03 [0.93-1.14] (random-effects, $I^2 = NA$ )
				Adjustment for histology as a potential confounder	Mortality (Yes) (Continuous lag-time variable)	HR: 1.02 [0.99-1.05] (random-effects, $I^2 = 26.2\%$ )
					Mortality (No) (Continuous lag-time variable)	HR: 1.07 [0.94-1.23] (random-effects, $I^2 = 72.0\%$ )
				Adjustment for residual	Mortality (Yes)	<b>HR: 1.07 [1.00-1.15] (random-effects, <math>I^2 = NA</math>)</b>

					disease as a potential confounder	(Continuous lag-time variable)		
						Mortality (No) (Continuous lag-time variable)	HR: 1.04 [0.98-1.09] (random-effects, I <sup>2</sup> = 54.6%)	
Loureiro (2017) (39)	PubMed/MEDLINE, EMBASE, Thomson Reuters, Web of Science Core Collection, ASTRO and ESTRO proceedings of annual meetings (2000-2013)	1,369	12	5,212	Excluding studies without WT to RT period restrictions	Mortality	HR: 1.0 [0.90-1.12]	Spain, Canada, Brazil, USA, Germany
Usón (2017) (45)	PubMed	239	12	12,056	Stepwise exclusion	Mortality, 3-year	<b>OR: 1.17 [1.05-1.29] (fixed-effects)</b>	Not reported
Zhan (2017) (42)	PubMed, EMBASE, Web of Science, Cochrane library, ASCO meeting abstracts	2,390	12	78,462	Excluding the largest 2 studies	Mortality	<b>HR: 1.10 [1.08-1.12] (random-effects, I<sup>2</sup> = 43.5%)</b>	Italy, France, Denmark, USA, UK, China
					Publication year	Mortality (1999)	<b>HR: 2.15 [1.2-3.85] (random-effects, I<sup>2</sup> = %NA)</b>	
						Mortality (2005)	HR: 0.00 [0.02-1.05] (random-effects, I <sup>2</sup> = 0%)	
						Mortality (2006)	<b>HR: 1.22 [1.11-1.34] (random-effects, I<sup>2</sup> = 0%)</b>	
						Mortality (2013)	<b>HR: 1.08 [1.06-1.10] (random-effects, I<sup>2</sup> = NA)</b>	
						Mortality (2014)	<b>HR: 1.10 [1.06-1.15] (random-effects, I<sup>2</sup> = 0%)</b>	
						Mortality (2015)	<b>HR: 1.32 [1.23-1.41] (random-effects, I<sup>2</sup> = 0%)</b>	
Mortality (2016)	<b>HR: 1.13 [1.08-1.19] (random-effects, I<sup>2</sup> = 0%)</b>							
Excluding the largest study	Worsened DFS	<b>HR: 1.09 [1.03-1.14]</b>						
Wu (2018) (32)	PubMed, EMBASE, MEDLINE, Cochrane Library	897	5	1,244	--			Not reported
Petrelli (2019) (35)	MEDLINE, EMBASE, Cochrane Library	8,752	34	141,853	--			Canada, US, Sweden, Netherlands, UK, Brazil, Korea, Denmark, Taiwan, Italy, Japan, China

Zhao (2019) (21)	PubMed, EMBASE, Medline, Cochrane, ClinicalTrials.gov	258	8	885	Treatment type	Disease progression (Melphalan-prednisone)	<b>RR: 0.22 [0.08-0.64] (random-effects, I<sup>2</sup> = 59%)</b>	Not reported
						Disease progression (bisphosphonate)	RR: 1.00 [0.83-1.21] (random-effects, I <sup>2</sup> = 0%)	
						Disease progression (immunomodulatory drug)	<b>RR: 0.43 [0.31-0.59] (random-effects, I<sup>2</sup> = 0%)</b>	
						Disease progression (Monoclonal antibody)	RR: 0.87 [0.36-2.07] (random-effects, I <sup>2</sup> = NA)	
					Treatment type	Mortality (Melphalan-prednisone)	RR: 1.05 [0.82-1.35] (fixed-effects, I <sup>2</sup> = 37%)	
						Mortality (bisphosphonate)	RR: 0.76 [0.18-3.29] (fixed-effects, I <sup>2</sup> = NA)	
						Mortality (immunomodulatory drug)	RR: 0.63 [0.38-1.04] (fixed-effects, I <sup>2</sup> = 34%)	
						Mortality (Monoclonal antibody)	RR: 0.73 [0.17-3.08] (fixed-effects, I <sup>2</sup> = 33%)	
					High-risk SMM	Disease progression	<b>RR: 0.51[0.37-0.70] (fixed-effects, I<sup>2</sup> = 47%)</b>	
					High-risk SMM	Mortality	<b>RR: 0.53 [0.29-0.97] (fixed-effects, I<sup>2</sup> = 0%)</b>	

AC, adjuvant chemotherapy; CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; LR, local recurrence; OR, odds ratio; OS, overall survival; pCR, pathological complete response; RCT, randomized controlled trial; RR, risk ratio; SMM, smoldering multiple myeloma

Significant pooled risk estimates are bolded.

--, indicate that subgroup and/or sensitivity analyses were not conducted or were not available.